**Coronavirus Disease 2019 (COVID-19)**

Updated twice weekly on Tuesdays and Fridays, and current as of 3:00 p.m. on the date it was posted.

This document is a collation of resources for your reference. For official guidance on COVID-19 in Ontario, please visit the Ministry of Health.

### Table of Contents

1. **New Content**
2. **Public Health Agencies**
   - Public Health Agency of Canada | canada.ca
   - BC Centre for Disease Control | bccdc.ca
   - Institut national de santé publique
   - International (outside of Canada)
   - CDC: Centers for Disease Control and Prevention | cdc.gov
   - ECDC: European Centre for Disease Prevention and Control | ecdc.europa.eu
   - FDA: U.S. Food & Drug Administration | fda.gov
   - Public Health England | gov.uk
   - World Health Organization | who.int
3. **Other relevant government bodies / health care organizations**
4. **CIDRAP: Center for Infectious Disease Research Policy | cidrap.umn.edu**
5. **National Collaborating Centre for Environmental Health | ncceh.ca**
6. **Updated Daily**
7. **COVID-19 resources (case counts) | arcgis.com**
8. **COVID-19 Canada Open Data Working Group | COVID-19 CODWG**
9. **Johns Hopkins CCSE | systems.jhu.edu**
10. **NextStrain | nextstrain.org**
11. **Guidelines and Technical documents (updated weekly)**
12. **Section I: General Guidelines**

**Ontario / Canada Main Page**
<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reopening/Rebuilding Guidelines</td>
<td>10</td>
</tr>
<tr>
<td>Vaccinations- General</td>
<td>11</td>
</tr>
<tr>
<td>Vaccinations- Specific populations</td>
<td>16</td>
</tr>
<tr>
<td>Vaccinations- Adverse Effects</td>
<td>18</td>
</tr>
<tr>
<td>Background Information/Case Definitions</td>
<td>19</td>
</tr>
<tr>
<td>Laboratories</td>
<td>20</td>
</tr>
<tr>
<td>Miscellaneous Guidelines</td>
<td>22</td>
</tr>
<tr>
<td>Data &amp; Surveillance</td>
<td>23</td>
</tr>
<tr>
<td>Variants – Omicron</td>
<td>24</td>
</tr>
<tr>
<td>Testing</td>
<td>24</td>
</tr>
<tr>
<td>Symptoms/Treatment</td>
<td>27</td>
</tr>
<tr>
<td>COVID-19 Diagnosis in Children</td>
<td>28</td>
</tr>
<tr>
<td>Post-COVID-19 Condition</td>
<td>29</td>
</tr>
<tr>
<td>Case Investigation &amp; Contact Tracing</td>
<td>29</td>
</tr>
<tr>
<td>Infection Prevention and Control</td>
<td>30</td>
</tr>
<tr>
<td>Section II: Guidelines for Health Sectors</td>
<td>32</td>
</tr>
<tr>
<td>Healthcare Providers</td>
<td>32</td>
</tr>
<tr>
<td>First Responders, Dentistry, Pharmacy, and Allied Health</td>
<td>33</td>
</tr>
<tr>
<td>Death Services</td>
<td>33</td>
</tr>
<tr>
<td>Congregate Living (including Long-Term Care, Prisons, and Shelters)</td>
<td>34</td>
</tr>
<tr>
<td>Section III: Guidelines for the Community</td>
<td>35</td>
</tr>
<tr>
<td>Travel, Transport &amp; Borders</td>
<td>35</td>
</tr>
<tr>
<td>Schools / Childcare</td>
<td>36</td>
</tr>
<tr>
<td>Mental Health /Addiction /Inequity</td>
<td>37</td>
</tr>
<tr>
<td>Community</td>
<td>38</td>
</tr>
<tr>
<td>Businesses/Workplaces</td>
<td>39</td>
</tr>
<tr>
<td>Masks (Non-Medical)</td>
<td>40</td>
</tr>
</tbody>
</table>
New Content

Public Health Agencies

Public Health Agency of Canada | canada.ca
Instead of daily case counts and vaccinations, starting the week of December 6, 2021 we will be reporting weekly trends. For daily case counts, you can still check 2019 novel coronavirus: outbreak update, or COVID-19 vaccination in Canada for vaccination rates.

- COVID-19: summary data about travellers, testing and compliance [updated 03-28-2022]
- Canada COVID-19 weekly epidemiology report: 13 March to 19 March 2022 (week 11) [03-25-2022]
- Vaccine coverage: This report was last updated on March 25, 2022 with data up to and including March 20, 2022.
  - 85.36% of the population 5 years and older are fully vaccinated
- Statement from the Chief Public Health Officer of Canada [03-25-2022]
- Mathematical modelling and COVID-19 [updated regularly]
- COVID-19 daily epidemiology update [updated regularly]
- COVID-19 data trends [updated regularly]

BC Centre for Disease Control | bccdc.ca
- COVID-19: viral testing guidelines for British Columbia [updated 03-23-2022]

Institut national de santé publique | inspq.qc.ca
- SRAS-CoV-2 : Gestion des travailleurs de la santé en milieux de soins [04-01-2022]
- Portrait des décès liés à la COVID-19 au Québec - En date du 12 mars 2022 [03-31-2022]
- Comparaison des durées de séjour hospitalier selon le variant présomptif, chez les patients hospitalisés avec un diagnostic de COVID-19 [03-31-2022]
- Monitoring of suicidal ideation and suicide attempts during COVID-19 from the Emergency Management Information System [03-30-2022]
- SRAS-CoV-2 : Gestion des travailleurs de la santé en milieux de soins [03-29-2022]
- Reducing social inequalities in health (SIH): working together toward a more equitable, healthier and resilient society [03-29-2022]

International (outside of Canada)

CDC: Centers for Disease Control and Prevention | cdc.gov
- COVID Data Tracker weekly review [04-01-2022]
  - “As the country emerges from the Omicron surge—and we experience low COVID-19 Community levels in most parts of the country—CDC has updated its COVID-19 vaccination guidance to give some people the option to get a second mRNA COVID-19
booster dose (Pfizer-BioNTech or Moderna). You can now receive a second booster dose if you:

- Received the Johnson & Johnson/Janssen vaccine as both your primary and booster dose at least four months ago*
- Are ages 50 years and older and received any booster dose at least four months ago
- Are moderately or severely immunocompromised, ages 12 years and older, and received any booster dose at least four months ago

As of March 30, 2022, the current 7-day moving average of daily new cases (25,732) decreased 3.0% compared with the previous 7-day moving average (26,518). A total of 79,904,464 COVID-19 cases have been reported in the United States as of March 30, 2022.

CDC Nowcast projections* for the week ending March 26, 2022, estimate the combined national proportion of lineages designated as Omicron to be 100%. There are five lineages designated as Omicron: B.1.1.529, BA.1, BA.1.1, BA.2, and BA.3. COVID Data Tracker shows the proportions of the B.1.1.529 lineage (includes BA.1 and BA.3), the BA.1.1** lineage, and the BA.2 lineage. The predominant Omicron lineage in the United States is BA.2. The national proportion of BA.2 is projected to be 54.9% (95% PI 50.8-59.1%). BA.1.1 is projected to be 40.4% (95% PI 36.4-44.5%) and B.1.1.529 (BA.1 and BA.3) is projected to be 4.7% (95% PI 3.9-5.7%). Omicron is predicted to be 100% in all HHS regions.”

- Cases in the U.S. [03-31-2022]
- Overall US COVID-19 vaccine distribution and administration update as of Thu, 31 Mar 2022 06:00:00 EST [03-31-2022]
- New CDC data illuminate youth mental health threats during the COVID-19 pandemic [03-31-2022]
- SUPPLEMENTS: Disruptions to school and home life among high school students during the COVID-19 pandemic — adolescent behaviors and experiences survey, United States, January–June 2021 [03-31-2022]
- SUPPLEMENTS: Perceived racism and demographic, mental health, and behavioral characteristics among high school students during the COVID-19 pandemic — Adolescent behaviors and experiences survey, United States, January–June 2021 [03-31-2022]
- SUPPLEMENTS: Mental health, suicidality, and connectedness among high school students during the COVID-19 pandemic — adolescent behaviors and experiences survey, United States, January–June 2021 [03-31-2022]
- SUPPLEMENTS: Use of tobacco products, alcohol, and other substances among high school students during the COVID-19 pandemic — adolescent behaviors and experiences survey, United States, January–June 2021 [03-31-2022]
- CDC media telebriefing: new CDC data illuminate youth mental health threats during the COVID-19 pandemic [03-31-2022]
- Quarantine and isolation [updated 03-30-2022]
- COVID-19 vaccine booster shot [updated 03-30-2022]
- COVID-19 forecasts: deaths [03-30-2022]
- Investigating long-term effects of myocarditis [03-29-2022]
- COVID-19 vaccine equity for racial and ethnic minority groups [03-29-2022]
- Tribal communities [updated 03-29-2022]
- Selected adverse events reported after COVID-19 vaccination [updated 03-28-2022]
• Previous COVID-19 forecasts: hospitalizations [03-30-2022]
• Effectiveness of homologous and heterologous COVID-19 booster doses following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) vaccine dose against COVID-19–associated emergency department and urgent care encounters and hospitalizations among adults — VISION Network, 10 states, December 2021–March 2022 [03-29-2022]
• CDC recommends additional boosters for certain individuals [03-29-2022]

ECDC: European Centre for Disease Prevention and Control | ecdc.europa.eu
• Communicable disease threats report, 27 March–2 April 2022, week 13 [04-01-2022]
• Country overview report: week 12 2022 [04-01-2022]
  o “At the end of week 12 2022 (week ending Sunday, 27 March), the epidemiological situation in the EU/EEA was characterised by a continued but slowed increase in case rates (by 4.6%, compared with the previous week). A proportionally higher increase of 14% continued to be observed among people aged 65 years and older. Increases in this age group were observed in 17 of 26 countries with data. The case rate among those aged 65 years and older is now as high as the previous peak observed during the initial Omicron wave.
  o In week 12, level of ICU occupancy or admission continued to remain much lower than previously observed, with no countries reporting levels above 50% of their pandemic maximum. Increases were reported in four countries (Austria, Ireland, Luxembourg and Slovenia). In addition, the EU/EEA death rate continued to decrease (by 11%, compared with the previous week 11).
  o The overall COVID-19 case notification rate for the EU/EEA was 1 932 per 100 000 population (1 857 the previous week). This rate has been increasing for three weeks. The 14-day COVID-19 death rate (28.3 deaths per million population, compared with 32.2 deaths the previous week) has been decreasing for five weeks. Of 28 countries with data on hospital or ICU admissions or occupancy up to week 12, nine reported an increasing trend in at least one of these indicators compared with the previous week.
  o Forecasts of cases, hospital admissions and deaths from the European COVID-19 Forecast Hub provide predictions for weeks 13 and 14. Compared with the previous week, decreasing trends in cases, stable trends in hospital admissions, and stable trends in deaths are forecast overall for the EU/EEA by the end of week 14. Forecasts for individual countries may differ from those for the EU/EEA as a whole. Note that forecasts of cases are considered to be increasingly unreliable due to changes in testing criteria and reporting procedures. All current forecasts, in particular case forecasts, should be treated with caution.
  o By the end of week 12, the cumulative uptake of the primary course of COVID-19 vaccination in the EU/EEA was 83.3% (country range: 35.1–94.8%) among adults aged 18 years and older and 72.4% (country range: 29.5–86.1%) in the total population. The cumulative uptake of a booster/additional dose was 63.4% (country range: 10.8–88.1%) among adults aged 18 years and older and 52.5% (country range: 8.8–70.4%) in the total population.
  o The estimated distribution (median and range of values from 20 countries for weeks 10 – 11, 7 March to 20 March 2022) of variants of concern (VOCs) was 99.9% (63.9–100.0%) for B.1.1.529 (Omicron) and 0.0% (0.0–1.9%, 74 detections) for B.1.617.2 (Delta).
The estimate distribution of Omicron sublineages in this period from 17 countries reporting data on sublineages at an adequate sequencing volume was 75.4% (37.8–98.8%) for BA.2, 21.8% (1.2–51.5%) for BA.1 and 0.3% (0.0–0.7%, 9 detections) for BA.3.”

- **COVID-19 situation update worldwide, as of week 12 updated 31 March 2022** [03-31-2022]
- **Data on SARS-CoV-2 variants in the EU/EEA** [03-31-2022]
- **COVID-19 situation update for the EU/EEA, as of 30 March 2022** [03-30-2022]
- **Infographic: considerations for the provision of immunisation services to people fleeing Ukraine and the prevention of vaccine-preventable disease outbreaks** [03-30-2022]
- **Data on the daily number of new reported COVID-19 cases and deaths by EU/EEA country** [updated regularly]
- **Data on COVID-19 vaccination in the EU/EEA** [updated regularly]

**FDA: U.S. Food & Drug Administration | fda.gov**

- **Coronavirus (COVID-19) update: daily roundup** [updated regularly]
- **FDA Roundup: March 29, 2022** [03-29-2022]
  - Today, the FDA authorized a manufacturing change for the Moderna COVID-19 vaccine to include an additional presentation of the vaccine for booster vaccination doses only. [...]  
  - As part of the FDA’s effort to protect consumers, the agency issued warning letters jointly with the Federal Trade Commission to two companies for selling unapproved products with unproven COVID-19 claims. [...]  
  - As part of the FDA’s effort to protect consumers, the agency issued warning letters jointly with the Federal Trade Commission to seven companies for selling CBD products using research studies to claim or imply misleadingly that their CBD products will cure, mitigate, treat or prevent COVID-19. Consumers concerned about COVID-19 should consult with their health care provider. [...]  
- **COVID-19 test development and review: FAQs on testing for SARS-CoV-2** [updated 03-29-2022]
- **Coronavirus (COVID-19) update: FDA authorizes second booster dose of two COVID-19 vaccines for older and immunocompromised individuals** [03-29-2022]

**Public Health England | gov.uk**

*Note: Public Health England was replaced by UK Health Security Agency and Office for Health Improvement and Disparities. These organizations are listed below under “Other relevant government organizations”*

- **Location of Public Health England (PHE) functions from 1 October 2021**

**World Health Organization | who.int**

- **WHO launches guidance on digitally documenting SARS-CoV-2 test results** [03-31-2022]
- **Digital documentation of COVID-19 certificates: test result: technical specifications and implementation guidance, 31 March 2022** [03-31-2022]
- **WHO Director-General’s opening remarks at the WHO press conference** [03-30-2022]
  - “Based on what we know now, the most likely scenario is that the virus continues to evolve, but the severity of disease it causes reduces over time as immunity increases due to vaccination and infection. Periodic spikes in cases and deaths may occur as
immunity wanes, which may require periodic boosting for vulnerable populations. In the best-case scenario, we may see less severe variants emerge, and boosters or new formulations of vaccines won't be necessary. In the worst-case scenario, a more virulent and highly transmissible variant emerges. Against this new threat, people's protection against severe disease and death, either from prior vaccination or infection, will wane rapidly. Addressing this situation would require significantly altering the current vaccines and making sure they get to the people who are most vulnerable to severe disease. So how do we move forward, and end the acute phase of the pandemic this year? It requires countries to invest in five core components: First, surveillance, laboratories, and public health intelligence; Second, vaccination, public health and social measures, and engaged communities; Third, clinical care for COVID-19, and resilient health systems; Fourth, research and development, and equitable access to tools and supplies; And fifth, coordination, as the response transitions from an emergency mode to long-term respiratory disease management. We have all the tools we need to bring this pandemic under control: we can prevent transmission with masks, distancing, hand hygiene and ventilation; And we can save lives by ensuring everyone has access to tests, treatments and vaccines. Equitable vaccination remains the single most powerful tool we have to save lives. Striving to vaccinate 70% of the population of every country remains essential for bringing the pandemic under control, with priority given to health workers, older people and other at-risk groups.”

- **Strategic preparedness, readiness and response plan to end the global COVID-19 emergency in 2022** [03-30-2022]
- **WHO releases 10-year strategy for genomic surveillance of pathogens** [03-30-2022]
- **Global genomic surveillance strategy for pathogens with pandemic and epidemic potential, 2022–2032** [03-28-2022]
- **Coronavirus disease (COVID-19) weekly operational update** [03-30-2022]
- **Coronavirus disease (COVID-19) weekly epidemiological update** [03-29-2022]
- **Egypt and Nigeria medicines regulators achieve high maturity level in WHO classification and WHO launches list of regulatory authorities that meet international standards** [03-30-2022]
- **Acknowledgements: the Unity Studies for sero-epidemiological investigation of COVID-19** [03-24-2022]
- **Log of major changes and errata in WHO daily aggregate case and death count data** [updated regularly]
- **Draft landscape and tracker of COVID-19 candidate vaccines** [updated regularly]
- **Coronavirus disease (COVID-19) press briefings** [audio posted first; transcripts posted later]
- **EPI-WIN: WHO information network for epidemics** [updated regularly]

**Other relevant government bodies / health care organizations**

- Indigenous Services Canada
  - Coronavirus (COVID-19) and Indigenous communities [updated regularly]
  - Indigenous Services Canada COVID-19 update [03-31-2022]
- Statistics Canada
  - COVID-19: a data perspective [updated regularly]
  - Personal protective equipment survey, January 2022 [03-31-2022]
  - Examining businesses’ needs for personal protective equipment [03-31-2022]
- Provisional death counts and excess mortality, January 2020 to December 2021 [03-30-2022]
- Sense of meaning and purpose in Canada, October to December 2021 [03-30-2022]
- Study: measuring the correlation between COVID-19 restrictions and economic activity [03-28-2022]

- UK Health Security Agency
  - COVID-19: managing healthcare staff with symptoms of a respiratory infection [04-01-2022]
  - Living safely with respiratory infections, including COVID-19 [04-01-2022]
  - Reducing the spread of respiratory infections, including COVID-19, in the workplace
  - COVID-19: management of staff and exposed patients and residents in health and social care settings [updated 04-01-2022]
  - The R value and growth rate [updated 04-01-2022]
  - COVID-19 rapid lateral flow test kit instructions: SureScreen [updated 04-01-2022]
  - COVID-19 rapid lateral flow test kit instructions: ACON Flowflex [updated 04-01-2022]
  - Coronavirus (COVID-19) PCR home test kit instructions [updated 04-01-2022]
  - PCR home testing for people eligible for new COVID-19 treatments [updated 04-01-2022]
  - Throat and nose test (Innova 25) for care home staff: COVID-19 rapid test kit instructions [updated 04-01-2022]
  - How to do a coronavirus (COVID-19) rapid lateral flow test [updated 04-01-2022]
  - COVID-19 rapid lateral flow test kit instructions: throat and nose test [updated 04-01-2022]
  - National protocol for Comirnaty® 30microgram/dose COVID-19 mRNA vaccine [updated 04-01-2022]
  - National protocol for Spikevax (formerly COVID-19 Vaccine Moderna) [updated 04-01-2022]
  - National protocol for COVID-19 Vaccine AstraZeneca (ChAdOx1-S [recombinant]) [updated 04-01-2022]
  - National protocol for Comirnaty® 10 microgram/dose COVID-19 mRNA vaccine [updated 04-01-2022]
  - Coronavirus (COVID-19) testing for anyone working in adult social care who is not part of regular testing at work [updated 04-01-2022]
  - Coronavirus (COVID-19) testing for adult day care centre workers and service users [updated 04-01-2022]
  - Coronavirus (COVID-19) testing for homecare workers [updated 04-01-2022]
  - Coronavirus (COVID-19) testing in extra care and supported living settings [updated 04-01-2022]
  - Coronavirus (COVID-19): testing in adult care homes [updated 04-01-2022]
  - COVID-19: guidance on protecting people defined on medical grounds as extremely vulnerable [updated 04-01-2022]
• SAMBA II SARS-CoV-2/RSV Test: technical validation protocol [03-31-2022]
• SAMBA II SARS-CoV-2/FluA/FluB Test: technical validation report [03-31-2022]
• UKHSA response to ZOE COVID Study enquiries [03-31-2022]
• Coronavirus (COVID-19) testing for adult social care services [updated 03-31-2022]
• COVID-19 vaccine weekly surveillance reports (weeks 39 to 13, 2021 to 2022) [updated 03-31-2022]
• National flu and COVID-19 surveillance reports: 2021 to 2022 season [updated 03-31-2022]
• COVID-19 test validation approved products [updated 03-30-2022]
• Assessment and procurement of coronavirus (COVID-19) tests [updated 03-30-2022]
• COVID-19: adult surveillance [updated 03-29-2022]

• UK Department of Health and Social Care
  • Infection prevention and control in adult social care: COVID-19 supplement [03-31-2022]

• Centre for Global Infectious Disease Analysis
  • Report 51 - Valuing lives, education and the economy in an epidemic: societal benefit of SARS-CoV-2 booster vaccinations in Indonesia [02-14-2022]

CIDRAP: Center for Infectious Disease Research Policy | cidrap.umn.edu
• Vaccines offer substantial extra protection after COVID-19 infection [04-01-2022]
• News Scan for Apr 01, 2022: COVID-19 antiviral efficacy; CWD now in North Carolina; Resistant E coli in Kenyan children; Polio in 4 countries
• Ivermectin doesn't prevent COVID hospital cases, large study finds [03-31-2022]
• COVID vaccine prevents 40% of Omicron hospital stays in teens, 68% in kids [03-31-2022]
• CDC: 37% of US teens had poor mental health in pandemic [03-31-2022]
• Global COVID cases ebb amid testing blind-spot worries [03-30-2022]
• White House launches 'one-stop' website for COVID-19 needs [03-30-2022]
• News Scan for Mar 30, 2022: Long-term COVID lung damage; COVID-19 taste loss
• FDA OKs second COVID booster shot for older Americans [03-29-2022]
• Black cancer patients more likely than Whites to have severe COVID [03-29-2022]
• News Scan for Mar 29, 2022: Outcomes of long COVID; Antibiotic resistance in food pathogens

National Collaborating Centre for Environmental Health | ncceh.ca
• March, 2022 environmental health research scan (with COVID-19 section) [03-16-2022]
• The Omicron variant - updating our knowledge as the surge subsides [02-15-2022]
• February, 2022 environmental health research scan (with COVID-19 section) [02-14-2022]

ProMED | promedmail.org
• Latest on COVID-19 [individual posts]
• COVID-19 update (86): lung damage, taste loss, cases, vacc. comparison, WHO [03-31-2022]
• COVID-19 update (85): racial disparities, long COVID, China, 2nd booster, WHO [03-30-2022]
• COVID-19 update (84): ophthalmologic eff., immunity, cont. tracing, booster, WHO [03-30-2022]
• COVID-19 update (83): animal, USA, mule deer [03-29-2022]

Updated Daily

COVID-19 resources (case counts) | arcgis.com
- Canada COVID-19

COVID-19 Canada Open Data Working Group | COVID-19 CODWG
- COVID-19 in Canada (case count dashboard)

Johns Hopkins CCSE | systems.jhu.edu
- 2019-nCoV Global Cases (by Johns Hopkins CSSE) [real-time tracking]
- Resetting our response: changes needed in the US approach to COVID-19 [07-29-2020]

NextStrain | nextstrain.org
- Phylogeny of SARS-like betacoronaviruses including novel coronavirus (nCoV) [real-time tracking]
- Genomic epidemiology of novel coronavirus (nCoV) [real-time tracking]
- Genomic analysis of nCoV spread. Situation report 2020-01-30 [real-time tracking]

Guidelines and Technical documents (updated weekly)
The guidelines listings are current to 04-01-2022; posted 04-01-2022

Section I: General Guidelines

Ontario / Canada Main Page
- Ontario guidance
- Canadian guidance (federal)

Reopening/Rebuilding Guidelines

Ontario
- ON COVID-19 public health measures and advice [no date]

Canada (federal) and provinces and territories (other than Ontario)
- CA COVID-19: readiness criteria and indicators for easing restrictive public health measures [05-14-2021]
- BC B.C.'s response to COVID-19 [updated 03-23-2022]
- AB COVID-19 public health actions [no date]
- SK Public health measures [no date]
- MB Manitoba Pandemic Response System [no date]
- QC About the measures in force [no date]
- NB Living with COVID-19 [no date]
- NL Current Restrictions [no date]
- PEI COVID-19 (coronavirus) in Prince Edward Island [no date]
- NS Reopening plan [updated regularly]
- NW Restrictions and Moving Forward [no date]
- YT Forging ahead: the Yukon's continuing response to COVID-19 [no date]
- NT Nunavut’s Path: Living with COVID-19 [03/14/2022]
- Guidance on re-opening northern, remote, isolated, and Indigenous communities [no date]

WHO
- Implementation guidance for assessments of frontline service readiness [07-01-2021]
- Considerations for implementing and adjusting public health and social measures in the context of COVID-19: interim guidance [06-14-2021]
- Considerations for implementing and adjusting public health and social measures in the context of COVID-19 [11-04-2020]
- WHO COVID-19 preparedness and response progress report - 1 February to 30 June 2020 [08-03-2020]

UK
- Coronavirus (COVID-19): guidance on the phased return of elite sport [updated 03-22-2022]
- Our plan to rebuild: the UK government’s COVID-19 recovery strategy [07-24-2020]

ECDC
- Data on country response measures to COVID-19 [updated 03-17-2022]
- Introducing a coherent European framework for tuning COVID-19 response measures [03-17-2021]

Vaccinations- General

Ontario Ministry of Health
- COVID-19 vaccine-relevant information and planning resources [updated 03-25-2022]
- Guidance for routine immunization services during COVID-19 version 2 [10-28-2021]
- Ethical framework for COVID-19 vaccine distribution [09-23-2021]

Canada (Federal)
- COVID-19 vaccine guide for youth and adults (12 years and over): Overview [02-02-2022]
- Adjusting public health measures in the context of COVID-19 vaccination [02-02-2022]
- Planning guidance for immunization clinics for COVID-19 vaccines [12-17-2021]
- An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI) guidance on booster COVID-19 vaccine doses in Canada [12-03-2021]
- Summary of NACI rapid response of December 3, 2021: guidance on booster COVID-19 vaccine doses in Canada [12-03-2021]
- NACI interim guidance on booster COVID-19 vaccine doses in Canada [10-29-2021]
- For immunization providers: Interim national vaccine storage, handling and transportation guidelines for ultra-low temperature and frozen temperature COVID-19 vaccines [09-16-2021]
- COVID-19 immunization: federal, provincial and territorial statement of common principles [modified 08-11-2021]
- Health care provider vaccine tool kit, version 2 [05-07-2021]
- Planning guidance for administration of COVID-19 vaccine [12-21-2020]
- Canada’s COVID-19 immunization plan: saving lives and livelihoods [no date]
- Recommendations on the duration of the post-vaccination observation period for influenza vaccination during the COVID-19 pandemic [10-14-2020]
- Interim guidance on continuity of immunization programs during the COVID-19 pandemic [05-13-2020]

Provinces and territories (other than Ontario)

- BC Spikevax™ (Moderna) [updated 03-18-2022]
- BC COVID-19 mRNA vaccine Comirnaty™ (Pfizer-BioNTech) [updated 03-18-2022]
- BC COVID-19 vaccine eligibility [updated 03-18-2022]
- BC Novavax shipping, storage and use guidelines [03-04-2022]
- BC Novavax redistribution guidelines [03-04-2022]
- BC Immunization manual: summary of changes: admin circular [03-04-2022]
- BC COVID-19 vaccine Nuvaxovid™ (Novavax) [updated 03-04-2022]
- BC COVID-19 vaccine screening checklist [02-25-2022]
- BC Vaxzevria™/COVISHED (AstraZeneca/Verity Pharmaceuticals) [updated 02-25-2022]
- BC COVID-19 Vaccine ChAdOx1-S [recombinant] [updated 02-25-2022]
- BC Pfizer redistribution guidelines [02-08-2022]
- BC World Health Organization (WHO) emergency use authorization (EUA) qualified COVID-19 vaccines [01-31-2022]
- BC Point of care risk assessment (PCRA) [no date]
- BC World Health Organization (WHO) emergency use authorization (EUA) qualified COVID-19 vaccines [01-31-2022]
- BC Janssen shipping, storage and use guideline [01-17-2022]
- BC Janssen redistribution guidelines [01-17-2022]
- BC Regulated and unregulated health professionals SARS-CoV-2 immunization order [01-09-2022]
- BC Emergency medical assistants SARS-CoV-2 immunization order [updated 01-09-2022]
- BC Moderna redistribution guidelines [01-06-2022]
- BC Administrative circular [12-31-2021]
- BC 2021/22 seasonal influenza vaccine eligibility [10-00-2021]
- BC COVID-19 Pfizer vaccine shipping, storage, thawing and use guidelines [10-15-2021]
- BC Latex content in vaccines [10-00-2021]
- BC Immunization manual appendix A: informed consent (page 4) [updated 09-00-2021]
- BC Guidance for receiving and handling the Pfizer-BioNTech COVID-19 mRNA vaccine (including dry ice procedures) [08-31-2021]
Tasks

- BC COVID-19 vaccination: why your 2nd dose is important [08-27-2021]
- BC Vaccine SOP: cold chain incident reporting process [updated 07-21-2021]
- BC Pfizer vaccine sub dose vial reporting [07-13-2021]
- BC COVID-19 Pfizer vaccine partial tray ULT distribution guidelines [05-19-2021]
- BC Cold chain assets warranty contact information [05-05-2021]
- BC Vaccine SOP: return of materials to manufacturers [04-30-2021]

WHO

- Interim recommendations for use of the Bharat Biotech BBV152 COVAXIN® vaccine against COVID-19 [03-15-2022]
- Interim recommendations for use of the inactivated COVID-19 vaccine BIBP developed by China National Biotec Group (CNBG), Sinopharm [updated 03-15-2022]
- Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac [03-15-2022]
- Annexes to the interim recommendations for use of the Bharat Biotech BBV152 COVAXIN® vaccine against COVID-19: Grading of evidence – Evidence to recommendations tables [03-15-2022]
- Annexes to the recommendations for use of the Sinovac-CoronaVac vaccine against COVID-19: grading of evidence, evidence to recommendation tables [03-15-2022]
- Interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19 (AstraZeneca COVID-19 vaccine AZD1222 Vaxzevria™, SII COVISHIELD™) [03-15-2022]
- Interim recommendations for use of the Moderna mRNA-1273 vaccine against COVID-19 [updated 02-23-2022]
- NVX-CoV2373 recombinant, adjuvanted COVID-19 vaccine [02-09-2022]
- Interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing [01-21-2022]
- COVAXIN® (BBV152) – Inactivated, COVID-19 vaccine [01-10-2022]
- Annexes to the interim recommendations for use of the Janssen Ad26.COV2.S vaccine [12-09-2021]
- Interim recommendations for the use of the Janssen Ad26.COV2.S (COVID-19) vaccine [12-09-2021]
- Guidance on operational microplanning for COVID-19 vaccination [11-16-2021]
- Annexes to WHO interim recommendations for use of the COVID-19 vaccine BIBP [10-28-2021]
- Coadministration of seasonal inactivated influenza and COVID-19 vaccines: interim guidance [10-21-2021]
- How to manage COVID-19 vaccines without VVM at vaccination service points? [08-31-2021]
- Training on handling, storing and transporting Pfizer BioNTech COVID-19 Vaccine COMIRNATY® (Tozinameran) [08-04-2021]
• COVID-19 vaccine introduction and deployment costing tool (CVIC tool) version 2.2 [06-10-2021]
• Guidance on developing a national deployment and vaccination plan for COVID-19 vaccines [06-01-2021]
• Background document on the inactivated vaccine Sinovac-CoronaVac against COVID-19: [06-01-2021]
• Technical note on delayed shipments for the ChAdOx1-S [recombinant] vaccines: what are the implications for the administration of second doses? Scientific brief [05-26-2021]
• Health worker communication for COVID-19 vaccination flow diagram [05-13-2021]
• AstraZeneca ChAdOx1-S/nCoV-19 [recombinant], COVID-19 vaccine: COVID-19 vaccine explainer [05-10-2021]
• Estimating COVID-19 vaccine effectiveness against severe acute respiratory infections (SARI) hospitalizations associated with laboratory-confirmed SARS-CoV-2: an evaluation using the test-negative design [05-07-2021]
• COVID-19 exercise programme - drills for vaccine deployment [05-03-2021]
• Why are there extra doses of vaccine in the vaccine vial? [04-16-2021]
• COVID-19 and mandatory vaccination: ethical considerations and caveats [04-13-2021]
• Data for action: achieving high uptake of COVID-19 vaccines: interim guidance [04-01-2021]
• Immunization as an essential health service: guiding principles for immunization activities during the COVID-19 pandemic and other times of severe disruption [11-01-2020]

CDC
• Stay Up to Date with Your COVID-19 Vaccines [updated 03-22-2022]
• Interim infection prevention and control recommendations for healthcare personnel during the coronavirus disease 2019 (COVID-19) pandemic [updated 03-22-2022]
• Understanding Viral Vector COVID-19 Vaccines [updated 03-14-2022]
• COVID-19 vaccine booster shots [updated 02-02-2022]
• COVID-19 vaccine reporting systems [updated 01-04-2022]
• Communication resources for COVID-19 vaccines [12-11-2021]
• COVID-19 vaccination clinical & professional resources [12-01-2021]
• COVID-19 vaccination program operational guidance [10-14-2021]
• Public health investigations of COVID-19 vaccine breakthrough cases: Case investigations protocol [no date]
• Interim guidance for routine and influenza immunization services during the COVID-19 Pandemic [04-15-2021]
• Expanding COVID-19 vaccine distribution to primary care providers to address disparities in immunization [04-14-2021]

UK
• National protocol for COVID-19 Vaccine AstraZeneca (ChAdOx1-S [recombinant]) [updated 03-29-2022]
• National protocol for Comirnaty® 30microgram/dose COVID-19 mRNA vaccine [updated 03-28-2022]
• **National protocol for Spikevax (formerly COVID-19 Vaccine Moderna)** [03-28-2022]
• **Monitoring reports of the effectiveness of COVID-19 vaccination** [updated 03-25-2022]
• **COVID-19 vaccination programme** [updated 03-17-2022]
• **COVID-19 vaccination: information for healthcare practitioners** [updated 03-10-2022]
• **COVID-19: the green book, chapter 14a** [updated 02-28-2022]
• **COVID-19 vaccination: vaccine product information** [02-23-2022]
• **COVID-19 vaccination: blood clotting information for healthcare professionals** [updated 02-14-2022]
• **COVID-19 vaccination: booster dose resources** [updated 02-02-2022]
• **National protocol for COVID-19 mRNA vaccine BNT162b2 (Pfizer/BioNTech)** [11-20-2021]
• **COVID-19 vaccination: what to expect after vaccination** [updated 11-09-2021]
• **Monitoring of the effectiveness of COVID-19 vaccination** [09-14-2021]
• **COVID-19: vaccine surveillance strategy** [03-29-2021]

**ECDC**

• **Interim analysis of COVID-19 vaccine effectiveness against Severe Acute Respiratory Infection due to laboratory-confirmed SARS-CoV-2 among individuals aged 30 years and older, ECDC multi-country study – second update** [03-14-2022]
• **Overview of the implementation of COVID-19 vaccination strategies and vaccine deployment plans in the EU/EEA** [01-31-2022]
• **Generic protocol for COVID-19 vaccine effectiveness studies during outbreaks in semi-closed settings in the EU/EEA** [12-14-2021]
• **Facilitating COVID-19 vaccination acceptance and uptake in the EU/EEA** [10-15-2021]
• **Infographic: facilitating COVID-19 vaccination acceptance and uptake** [10-15-2021]
• **Core protocol for ECDC studies of COVID-19 vaccine effectiveness against hospitalisation with severe acute respiratory infection laboratory-confirmed with SARS-CoV-2, version 1.0** [10-08-2021]
• **Interim public health considerations for the provision of additional COVID-19 vaccine doses** [09-01-2021]
• **Partial COVID-19 vaccination, vaccination following SARS-CoV-2 infection and heterologous vaccination schedule: summary of evidence** [07-22-2021]
• **Countering online vaccine misinformation in the EU/EEA** [06-29-2021]
• **Overview of EU/EEA country recommendations on COVID-19 vaccination with Vaxzevria, and a scoping review of evidence to guide decision-making** [05-18-2021]
• **Objectives of vaccination strategies against COVID-19** [04-23-2021]
• **Interim guidance on the benefits of full vaccination against COVID-19 for transmission and implications for non-pharmaceutical interventions** [04-21-2021]
• **Rollout of COVID-19 vaccines in the EU/EEA: challenges and good practice** [03-29-2021]
• **Stress test on logistical aspects of COVID-19 vaccination deployment plans: final report** [02-03-2021]
• **Integrated COVID-19 response in the vaccination era** [02-01-2021]
• **COVID-19 vaccination and prioritisation strategies in the EU/EEA** [12-22-2020]
Australia

- ATAGI recommendations on the use of a booster dose of COVID-19 vaccine [03/25/2022]
- Clinical recommendations for COVID-19 vaccines [updated 03/02/2022]
- COVID-19 vaccination – information on COVID-19 Pfizer (COMIRNATY) vaccine [updated 03-28-2022]
- ATAGI clinical guidance for COVID-19 vaccine providers [02/23/2022]
- COVID-19 vaccination – vaccine dose policy [updated 02-07-2022]
- COVID-19 vaccination – updated provider kit for general practices [12-14-2021]
- Op COVID SHIELD national COVID vaccine campaign plan [08-03-2021]

Vaccinations - Specific populations

Canada (Federal)

- NACI rapid response: Guidance on the use of booster COVID-19 vaccine doses in adolescents 12 to 17 years of age [modified 03-24-2022]
- NACI updated recommendations on the use of COVID-19 vaccines in children 5 to 11 years of age [modified 03-17-2022]
- COVID-19: recommendations for those vaccinated with vaccines not authorized by Health Canada for those staying in Canada to live, work or study [modified 03-11-2022]
- NACI rapid response: Updated guidance on COVID-19 vaccination timing for individuals previously infected with SARS-CoV-2 [modified 02-09-2022]
- Quick reference guide on use of COVID-19 vaccines for children 5 to 11 years of age: overview [modified 02-03-2022]
- Planning for the 2021-2022 school year in the context of COVID-19 vaccination [modified 02-02-2022]
- Archived: National Advisory Committee on Immunization (NACI) statement: recommendation on the use of the Pfizer-BioNTech COVID-19 vaccine (10 mcg) in children 5 to 11 years of age [updated 01-25-2022]
- NACI rapid response: updated recommendation on the use of authorized COVID-19 vaccines in individuals aged 12 years and older in the context of myocarditis and pericarditis reported following mRNA COVID-19 vaccines [12-03-2021]
- Summary of NACI rapid response of December 3, 2021: updated recommendation on the use of authorized COVID-19 vaccines in individuals aged 12 years and older in the context of myocarditis and pericarditis reported following mRNA COVID-19 vaccines [12-03-2021]

Provinces and territories (other than Ontario)

- BC COVID-19 mRNA vaccine Comirnaty™ (Pfizer-BioNTech) adult/adolescent [updated 03-18-2022]
- BC Health professionals COVID-19 vaccination status information and preventive measures – March 7, 2022 [03-08-2022]
- BC COVID-19 vaccination for children age 5-11 frequently asked questions for community practitioners [03-07-2022]
- BC RESIDENTIAL CARE COVID–19 VACCINATION STATUS [02-28-2022]

WHO
- Interim recommendations for an extended primary series with an additional vaccine dose for COVID-19 vaccination in immunocompromised persons [10-25-2021]
- Update on WHO Interim recommendations on COVID-19 vaccination of pregnant and lactating women [06-10-2021]
- Disability considerations for COVID-19 vaccination: WHO and UNICEF policy brief, 19 April 2021 [04-26-2021]

CDC
- COVID-19 vaccine equity for racial and ethnic minority groups [updated 03-29-2022]
- COVID-19 vaccines while pregnant or breastfeeding [updated 03-03-2022]
- COVID-19 vaccines for people who would like to have a baby [updated 03-03-2022]
- COVID-19 vaccination considerations for persons with underlying medical conditions [updated 02-25-2022]
- COVID-19 vaccine information for specific groups [updated 02-18-2022]
- Guidance for vaccinating older adults and people with disabilities: ensuring equitable covid-19 vaccine access [updated 01-20-2022]
- COVID-19 vaccines for children and teens [updated 01-11-2022]
- How to talk with parents and caregivers about COVID-19 vaccination [11-29-2021]
- Guidance for vaccinating older adults and people with disabilities at vaccination sites [08-10-2021]
- Interim guidance for health departments: COVID-19 vaccination implementation for people experiencing homelessness [4-30-2021]

UK
- COVID-19 vaccination: resources for children aged 5 to 11 years [updated 03-28-2022]
- COVID-19 vaccination: resources for children and young people aged 12 to 17 years [updated 02-01-2022]
- COVID-19 vaccination: women of childbearing age, currently pregnant or breastfeeding [updated 02-02-2022]
- Interim public health considerations for COVID-19 vaccination of children aged 5-11 years [12-01-2021]
- Safety of COVID-19 vaccines when given in pregnancy [04-30-2021]

ECDC
- Data collection on COVID-19 outbreaks in closed settings: long-term care facilities, version 2.1 [02-18-2022]
- COVID-19 vaccine effectiveness in adolescents aged 12–17 years and interim public health considerations for administration of a booster dose [02-08-2022]
- Interim public health considerations for COVID-19 vaccination of adolescents in the EU/EEA [06-01-2021]

Australia
- COVID-19 vaccination – COVID-19 vaccine information for the residential aged care workforce [03-29-2022]
- COVID-19 vaccination – COVID-19 vaccination decision guide for frail older people, including those in residential aged care facilities [updated 03-28-2022]
- COVID-19 vaccination – shared decision making guide for people receiving palliative care or end-of-life care [updated 03-28-2022]
- ATAGI – provider guide to COVID-19 vaccination of people with immunocompromise [updated 03-28-2022]
- ATAGI expanded guidance on temporary medical exemptions for COVID-19 vaccines [updated 02-25-2022]
- COVID-19 vaccination – vaccine dose policy- aged cared facilities [updated 02-07-2022]
- COVID-19 vaccination – COVID-19 vaccination decision guide for women who are pregnant, breastfeeding or planning pregnancy [updated 12-24-2021]

Vaccinations- Adverse Effects

Canada (Federal)
- National Advisory Committee on Immunization (NACI): rapid response: updated recommendation on the use of authorized COVID-19 vaccines in individuals aged 12 years and older in the context of myocarditis and pericarditis reported following mRNA COVID-19 vaccines [12-03-2021]
- Reports of myocarditis and pericarditis after COVID-19 vaccination: communiqué to health practitioners (June 3, 2021) [06-14-2021]

Provinces and territories (other than Ontario)
- BC Guidance document on the management of inadvertent vaccine errors [02-04-2022]
- BC Guidance on the Management of Inadvertent COVID-19 Vaccine Errors [02-04-2022]
- BC COVID-19 vaccine planning guide for people who are pregnant or breastfeeding [10-12-2021]
- BC Myocarditis/pericarditis in association with receipt of mRNA COVID-19 vaccine [06-11-2021]
- BC Summary of AEFI reporting criteria for COVID-19 vaccination for older children, adolescents and adults [no date]
- BC Clinical care guidance on vaccine-induced immune thrombotic thrombocytopenia (VITT), also known as thrombosis with thrombocytopenia syndrome (TTS) [04-30-2021]

CDC
- Interim considerations: preparing for the potential management of anaphylaxis after COVID-19 vaccination [02-11-2022]
- Possible side effects after getting a COVID-19 vaccine [01-12-2022]
- Lab tests to collect shortly after severe allergic reaction/anaphylaxis following COVID-19 vaccination [reviewed 08-09-2021]

WHO
- How to manage COVID-19 vaccines without VVM at vaccination service points? [08-31-2021]
- How to monitor and report COVID-19 vaccine side effects [03-15-2021]

**UK**
- Coronavirus (COVID-19) vaccine adverse reactions [updated 03-25-2022]
- COVID-19 vaccination: myocarditis and pericarditis information for healthcare professionals [updated 03-21-2022]
- Myocarditis and pericarditis after COVID-19 vaccination [updated 03-21-2022]
- COVID-19 vaccination: Guillain-Barré Syndrome information for healthcare professionals [updated 12-17-2021]
- Safety of COVID-19 vaccines when given in pregnancy [04-30-2021]

**Australia**
- ATAGI clinical guidance on COVID-19 vaccine administration errors [03-04-2022]
- COVID-19 vaccination – primary care approach to thrombosis with thrombocytopenia syndrome after COVID-19 AstraZeneca vaccine [updated 03-01-2022]
- COVID-19 vaccination – guidance on myocarditis and pericarditis after mRNA COVID-19 vaccines [12-02-2021]

**Background Information/Case Definitions**

**Ontario Ministry of Health**
- Ontario case definition - coronavirus disease (COVID-19) [01-17-2022]

**PHAC**
- National case definition: coronavirus disease (COVID-19) [updated 12-20-2021]
- COVID-19 case report form [01-11-2021]

**CDC**
- Coronavirus disease 2019 (COVID-19) 2020 interim case definition, approved August 5, 2020 [04-16-2021]

**WHO**
- A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021 [10-06-2021]

**ECDC**
- Reinfection with SARS-CoV-2: implementation of a surveillance case definition within the EU/EEA [04-08-2021]

**UK**
- COVID-19: background information [10-06-2021]
- COVID-19: epidemiology, virology and clinical features [10-06-2021]
Australia
- COVID-19 disease, symptoms and variants [updated 12-23-2021]

Other
- BMJ best practice COVID-19 [updated regularly]

Laboratories

Ontario Ministry of Health
- COVID-19 integrated testing & case, contact and outbreak management: interim guidance: Omicron surge version 3.0 amended [03-28-2022]
- Community labs and specimen collection centres: version 3 [03-29-2020]

PHAC
- Biosafety advisory: SARS-CoV-2 (severe acute respiratory syndrome-related coronavirus 2) [11-23-2021]
- Polymerase chain reaction (PCR) and cycle threshold (Ct) values in COVID-19 testing [06-10-2021]
- National polymerase chain reaction (PCR) testing indication guidance for COVID-19 [10-07-2020]
- Requirements for serological antibody tests submitted under the COVID-19 interim order: guidance [04-28-2020]

WHO
- Acknowledgements: the Unity Studies for sero-epidemiological investigation of COVID-19 [12-14-2021]
- Operational considerations to expedite genomic sequencing component of GISRS surveillance of SARS-CoV-2 [03-30-2021]
- Laboratory biosafety guidance related to coronavirus disease (COVID-19) [01-28-2021]
- COVID-19 new variants: knowledge gaps and research [01-12-2021]
- Genomic sequencing of SARS-CoV-2: a guide to implementation for maximum impact on public health [01-08-2021]
- SARS-CoV-2 genomic sequencing for public health goals [01-08-2021]
- SARS-CoV-2 antigen-detecting rapid diagnostic tests: an implementation guide [12-21-2020]
- Assessment tool for laboratories implementing SARS-CoV-2 testing [10-23-2020]
- Diagnostic testing for SARS-CoV-2: interim guidance [09-11-2020]
- Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassays [09-11-2020]

CDC
- Guidance for reporting SARS-CoV-2 sequencing results [03-21-2021]
- How to report COVID-19 laboratory data [updated 03-04-2022]
- Guidance for general laboratory safety practices during the COVID-19 pandemic [updated 03-02-2022]
- Using antibody tests for COVID-19 [updated 02-24-2022]
• Interim guidelines for COVID-19 antibody testing: interim guidelines for COVID-19 antibody testing in clinical and public health settings [updated 01-24-2022]
• Guidance for SARS-CoV-2 point-of-care and rapid testing [01-19-2022]
• Testing strategies for SARS-CoV-2 [updated 12-28-2021]
• Interim laboratory biosafety guidelines for handling and processing specimens associated with coronavirus disease 2019 (COVID-19) [12-13-2021]
• Frequently asked questions on COVID-19 testing for laboratories [11-12-2021]
• Science brief: SARS-CoV-2 infection-induced and vaccine-induced immunity [10-29-2021]
• Interim guidelines for collecting, handling, and testing clinical specimens for COVID-19 [10-25-2021]
• Evaluation for SARS-CoV-2 testing in animals [10-12-2021]
• Lab tests to collect shortly after severe allergic reaction/anaphylaxis following COVID-19 vaccination [08-09-2021]
• Interim guidance for use of pooling procedures in SARS-CoV-2 diagnostic and screening testing [06-30-2021]
• Variants and genomic surveillance for SARS-CoV-2 [04-02-2021]
• Resources for laboratories working on coronavirus (COVID-19) [03-28-2021]
• Information for laboratories about coronavirus (COVID-19) [03-28-2021]
• SARS-CoV-2 viral culturing at CDC [12-29-2020]
• Serology testing for COVID-19 at CDC [11-03-2020]

UK
• NHS test and trace statistics (England): methodology [updated 03-18-2022]
• Outcome of the evaluation of rapid diagnostic assays for specific SARS-CoV-2 antigens (lateral flow devices) [updated 03-14-2022]
• Protocol for evaluation of rapid diagnostic assays for specific SARS-CoV-2 antigens (lateral flow devices) [updated 03-14-2022]
• Technical validation protocol for SARS-CoV-2 nucleic acid detection [updated 03-14-2022]
• National standardised test performance process for manufacturers of SARS-CoV-2 virus antibody tests [updated 03-14-2022]
• Coronavirus (COVID-19) testing in adult care homes [updated 02-25-2022]
• How tests and testing kits for coronavirus (COVID-19) work [updated 02-14-2022]
• Surge testing for new coronavirus (COVID-19) variants [updated 08-16-2021]
• Maintaining records of staff, customers and visitors to support NHS Test and Trace [07-20-2021]
• COVID-19: guidance for sampling and for diagnostic laboratories [03-29-2021]

ECDC
• The use of antibody tests for SARS-COV-2 in the context of Digital Green Certificates [05-10-2021]

Australia
• PHLN guidance on laboratory testing for SARS-CoV-2 (the virus that causes COVID-19) [01-28-2022]
• BC PHO order on health authority regulated health professionals SARS-CoV-2 swabbing [11-16-2020]
• BC PHO order on midwives and certified practice speech language pathologists SARS-CoV-2 swabbing [11-16-2020]
• BC PHO order on British Columbia emergency health services SARS-CoV-2 swabbing [11-16-2020]

Miscellaneous Guidelines

PHAC
• COVID-19 and people with disabilities in Canada [updated 02-04-2022]
• Individual and community-based measures to mitigate the spread of COVID-19 in Canada [02-02-2022]
• COVID-19: safety advice for private indoor gatherings [12-23-2021]
• Federal/provincial/territorial public health response plan for ongoing management of COVID-19 [09-16-2021]

Canadian provinces and territories (other than Ontario)
• BC COVID-19 ethical decision-making framework [12-24-2020]

WHO
• Summary: Consolidated financing framework for ACT-accelerator agency and in-country needs [02-16-2022]
• Consolidated financing framework for ACT-A agency & in-country needs [02-09-2022]
• ACT-Accelerator 'fair share asks' - by country [02-09-2022]
• WHO technical consultation on oxygen access scale-up for COVID-19 [07-14-2021]
• Modelling the health impacts of disruptions to essential health services during COVID-19: Module 1: Understanding modelling approaches for sexual, reproductive, maternal, newborn, child and adolescent health, and nutrition [07-09-2021]
• Considerations in adjusting public health and social measures in the context of COVID-19: interim guidance [06-14-2021]
• Critical preparedness, readiness and response actions for COVID-19: interim guidance [05-27-2021]

CDC
• Wildfire smoke and COVID-19: frequently asked questions and resources for air resource advisors and other environmental health professionals [reviewed 01-31-2022]
• Public health guidance for potential COVID-19 exposure associated with travel [updated 01-27-2022]
• Return to work criteria for healthcare personnel with SARS-CoV-2 infection (interim guidance) [updated 01-21-2022]
• RRT composition: COVID-19 considerations [03-01-2021]
• **Managing investigations during an outbreak** [07-31-2020]
• **Optimizing supply of PPE and other equipment during shortages** [07-16-2020]

**ECDC**

• **One-day in-action review (IAR) protocol in the context of COVID-19** [03-00-2021]
• **Behavioural Insights research to support the response to COVID-19: a survey of implementation in the EU/EEA** [02-17-2021]
• **Conducting in-action and after-action reviews of the public health response to COVID-19** [06-04-2020]

**Australia**

• **CDNA National guidelines for public health units** [updated 03-22-2022]

**Other**

• **Public health ethics and COVID-19: selected resources** – National Collaborating Centre for Healthy Public Policy [11-30-2021]

**Data & Surveillance**

**Canada**

• **COVID-19 data trends** [modified 03-25-2022]
• **Mathematical modelling and COVID-19** [modified 02-18-2022]
• **National surveillance guidelines for coronavirus disease (COVID-19)** [03-19-2021]

**WHO**

• **Public health surveillance for COVID-19: interim guidance** [updated 02-14-2022]
• **End-to-end integration of SARS-CoV-2 and influenza sentinel surveillance: revised interim guidance** [01-31-2022]
• **Enhancing readiness for Omicron (B.1.1.529): technical brief and priority actions for Member States** [01-21-2022]

**CDC**

• **National wastewater surveillance system (NWSS)** [updated 03-21-2022]
• **Wastewater surveillance data reporting & analytics** [updated 03-08-2022]
• **Wastewater surveillance testing methods** [01-26-2022]
• **Public health interpretation and use of wastewater surveillance data** [01-26-2022]
• **Developing a wastewater surveillance sampling strategy** [01-26-2022]
• **Targeted wastewater surveillance at facilities, institutions, and workplaces** [01-26-2022]
• **COVID-19 serology surveillance** [03-11-2021]
• **Data visualization** [02-16-2021]
• **Guide to global digital tools for COVID-19 response** [10-23-2020]
• **Large-scale geographic seroprevalence surveys** [10-02-2020]

**ECDC**

• **Organisation of vector surveillance and control in Europe** [12-13-2021]
Surveillance of COVID-19 in long-term care facilities in the EU/EEA [11-29-2021]
Epidemiological update: Omicron variant of concern (VOC) – data as of 29 November 2021 (12:30) [11-29-2021]
COVID-19 variants: genonomically confirmed case numbers [updated 11-29-2021]
Threat assessment brief: implications of the emergence and spread of the SARS-CoV-2 B.1.1.529 variant of concern (Omicron) for the EU/EEA [11-26-2021]
COVID-19 surveillance guidance - transition from COVID-19 emergency surveillance to routine surveillance of respiratory pathogens [10-18-2021]
Guidance for representative and targeted genomic SARS-CoV-2 monitoring [05-03-2021]

UK

COVID-19 surveillance in school KIDs (sKIDs): pre and primary schools [09-04-2020]

Variants – Omicron

Canada
- SARS-CoV-2 variants: national definitions, classifications and public health actions [03-09-2022]

Ontario Ministry of Health

CDC
- Omicron variant: what you need to know [02-02-2022]

UK
- Investigation of SARS-CoV-2 variants: technical briefings [updated 03-25-2022]
- SARS-CoV-2 variants of public health interest [updated 03-25-2022]
- COVID-19: investigation and initial clinical management of possible cases [updated 03-25-2022]
- SARS-CoV-2 Omicron VOC: investigating and managing suspected or confirmed cases [updated 12-23-2021]
- Methods for the detection and characterisation of SARS-CoV-2 variants – first update [12-20-2021]

ECDC
- Assessment of the further emergence of the SARS-CoV-2 Omicron VOC in the EU/EEA, 19th update [updated 01-27-2022]
- Threat assessment brief: implications of the further emergence and spread of the SARS CoV-2 B.1.1.529 variant of concern (Omicron) fo the EU/EEA first update [12-02-2021]
- Epidemiological update: Omicron variant of concern (VOC) – data as of 30 November 2021 (12.00) [11-30-2021]
- Threat assessment brief: implications of the emergence and spread of the SARS-CoV-2 B.1.1.529 variant of concern (Omicron) for the EU/EEA [11-26-2021]

WHO
- Enhancing readiness for Omicron (B.1.1.529): technical brief and priority actions for member stats [updated 01-21-2022]

Testing

Canada
• Pan-Canadian COVID-19 testing and screening guidance: technical guidance and implementation plan [updated 09-08-2021]
• Interim guidance on the use of rapid antigen detection tests for the identification of SARS-CoV-2 infection [02-23-2021]
• Guidance for repeated PCR testing in individuals previously positive for COVID-19 [12-08-2020]
• National polymerase chain reaction (PCR) testing indication guidance for COVID-19 [10-07-2020]

Ontario Ministry of Health
• COVID-19 Integrated Testing & Case, Contact and Outbreak Management interim Guidance: Omicron Surge [amended 03-28-2022]
• COVID-19 test requisition [06-12-2021]
• Considerations for privately-initiated testing, version 3.0 [05-21-2021]
• COVID-19 guidance: considerations for rapid antigen screening, Version 2.0 [02-17-2021]
• Considerations for employer rapid antigen screening pilot [11-20-2020]
• COVID-19 surveillance testing – guidance regarding retirement homes staff and resident testing [06-09-2020]

Canadian provinces and territories (other than Ontario)
• BC COVID-19: viral testing guidelines for British Columbia [updated 03-23-2022]
• BC COVID-19 infection prevention and control: guidance for test collection & assessment centres [09-09-2021]
• BC Infection prevention and control guidance for test collection and assessment centres [09-09-2021]
• BC Antibody testing (serology) page [no date]
• BC Guideline for the appropriate use of SARS-CoV-2 (COVID-19) antibody (serology) testing [08-14-2020]

WHO
• Use of SARS-CoV-2 antigen-detection rapid diagnostic tests for COVID-19 self-testing [03-09-2022]

CDC
• Guidance for antigen testing for SARS-CoV-2 for healthcare providers testing individuals in the community [updated 03-04-2022]
• Using antibody tests for COVID-19 [updated 02-24-2022]
• SARS-CoV-2 antigen testing in long term care facilities [updated 02-17-2022]
• Interim guidance for SARS-CoV-2 testing in correctional and detention facilities [updated 02-15-2022]
• Overview of testing for SARS-CoV-2 (COVID-19) [updated 02-11-2022]
• Interim infection prevention and control recommendations for healthcare personnel during the coronavirus disease 2019 (COVID-19) pandemic [updated 02-02-2022]
• Interim infection prevention and control recommendations to prevent SARS-CoV-2 spread in nursing homes: nursing homes & long-term care facilities [updated 02-02-2022]
• Guidance for SARS-CoV-2 point-of-care and rapid testing [updated 01-19-2022]
• Testing strategies for SARS-CoV-2 [updated 12-28-2021]
• CDC’s diagnostic test for COVID-19 only and supplies [10-05-2021]
• Guidance for health departments about COVID-19 testing in the community [08-30-2021]
- **CDC diagnostic tests for covid-19** [08-07-2021]
- **Nucleic acid amplification tests (NAATs)** [06-14-2021]
- **Guidance for healthcare workers about COVID-19 (SARS-CoV-2) testing** [06-14-2021]
- **Performing broad-based testing for SARS-CoV-2 in congregate correctional, detention, and homeless service settings** [03-29-2021]
- **Serology testing for COVID-19 at CDC** [11-03-2020]

**UK**
- **Investigation of SARS-CoV-2 variants: technical briefings** [updated 03-25-2022]
- **Investigation of SARS-CoV-2 variants of concern: variant risk assessments** [updated 03-25-2022]
- **SARS-CoV-2 variants of public health interest** [updated 03-25-2022]
- **Testing for coronavirus (COVID-19) before hospital** [updated 03-08-2022]
- **Coronavirus COVID-19 serology and viral detection tests: technical validation reports** [updated 02-18-2022]
- **How tests and testing kits for coronavirus (COVID-19) work** [updated 02-14-2022]
- **Investigation of SARS-CoV-2 variants of concern: technical briefings** [09-17-2021]
- **Investigation of SARS-CoV-2 variants of concern – variant risk assessments for SARS-CoV-2 variant, Delta, 8 July 2021** [07-16-2021]
- **Investigation of SARS-CoV-2 variants of concern – variant risk assessments for SARS-CoV-2 variant, Lambda, 8 July 2021** [07-16-2021]
- **SARS-CoV-2 variant of concern diagnostic assurance** [07-15-2021]
- **SARS-CoV-2 RNA testing: assurance of positive results during periods of low prevalence** [10-16-2020]

**ECDC**
- **Considerations for the use of antibody tests for SARS-CoV-2 – first update** [02-10-2022]
- **Methods for the detection and identification of SARS-CoV-2 variants - first update** [12-20-2021]
- **Rapid assessment of antigenic characterisation capability and capacity for SARS-CoV-2 viruses in EU/EEA laboratories** [12-20-2021]
- **Options for the use of rapid antigen tests for COVID-19 in the EU/EEA and the UK** [10-26-2021]
- **Considerations on the use of rapid antigen detection (including self-) tests for SARS-CoV-2 in occupational settings** [05-06-2021]
- **Considerations for the use of saliva as sample material for COVID-19 testing** [05-03-2021]
- **Considerations on the use of self-tests for COVID-19 in the EU/EEA** [03-17-2021]
- **Guidance for COVID-19 quarantine and testing of travellers** [03-12-2021]
- **Detection and characterisation capability and capacity for SARS-CoV-2 variants within the EU/EEA** [02-16-2021]
- **Risk assessment: SARS-CoV-2 - increased circulation of variants of concern and vaccine rollout in the EU/EEA, 14th update** [02-15-2021]
- **COVID-19 testing strategies and objectives** [09-18-2020]
- **Objectives for COVID-19 testing in school settings** [08-10-2020]

**Australia**
- **PHLN and DCNA joint statement on SARS-CoV-2 rapid antigen tests** [updated 02-02-2022]
- **PHLN guidance on laboratory testing for SARS-CoV-2 (the virus that causes COVID-19)** [01-28-2022]

[Back to Top]
Symptoms/Treatment

Canada

- Considerations for the use of nirmatrelvir/ritonavir to treat COVID-19 in the context of limited supply [modified 02-24-2022]
- COVID-19 for health professionals: treatments [modified 02-01-2022]
- COVID-19 signs, symptoms and severity of disease: a clinician guide [modified 12-09-2021]
- Non-contact infrared thermometers (NCIT) [01-28-2021]

Ontario Ministry of Health

- COVID-19 reference document for symptoms v. 9.0 [updated 01-04-2022]
- COVID-19 patient screening guidance document version 5.0 [08-26-2021]

WHO

- COVID-19 disease in children and adolescents: scientific brief, 29 September 2021 [09-29-2021]
- Neurology and COVID-19: scientific brief, 29 September 2021 [09-29-2021]
- WHO living guideline: drugs to prevent COVID-19 [03-02-2021]
- Home care for patients with COVID-19 presenting with mild symptoms and management of their contacts: interim guidance [08-12-2020]

CDC

- Caring for post-COVID conditions [updated 03-21-2022]
- Clinical care quick reference for COVID-19 [updated 03-16-2022]
- Underlying medical conditions associated with higher risk for severe COVID-19: information for healthcare providers [updated 02-15-2022]
- Evidence used to update the list of underlying medical conditions that increase a person’s risk of severe illness from COVID-19 [updated 02-15-2022]
- If You Are Sick or Caring for Someone [02-09-2022]
- Ending home isolation for persons with COVID-19 not in healthcare settings [updated 01-14-2022]
- Ending isolation and precautions for people with COVID-19: interim guidance [updated 01-14-2022]
- Evaluating and caring for patients with post-COVID conditions: interim guidance [06-14-2021]
- Interim clinical guidance for management of patients with confirmed coronavirus disease (COVID-19) [02-16-2021]
COVID-19 Diagnosis in Children

Canada
- COVID-19 signs, symptoms and severity of disease: multisystem inflammatory syndrome - children (MIS-C) [12-09-2021]

Ontario
- Appendix 8: cases with positive COVID-19 serology results and management of cases with multisystem inflammatory syndrome in children (MIS-C) temporally associated with COVID-19, Version 2.0 [02-18-2021]

WHO

CDC
- Information for healthcare providers about multisystem inflammatory syndrome in children (MIS-C) [05-20-2021]

Other
- BC Children with immune compromise [11-30-2021]
Post-COVID-19 Condition
Canada
- Post COVID-19 condition [09-24-2021]

Ontario
- Science Table Understanding the post COVID-19 condition (long COVID) and the expected burden for Ontario [09-14-2021]

WHO
- Evaluating and caring for patients with post-COVID conditions: interim guidance [06-14-2021]
- Expanding our understanding of post COVID-19 condition: report of a WHO webinar - 9 February 2021 [04-24-2021]

CDC
- Caring for post-COVID conditions [03-21-2022]
- Post-COVID conditions: information for healthcare providers [07-09-2021]
- Evaluating and caring for patients with post-COVID conditions: interim guidance [06-14-2021]

UK
- Long-term effects of coronavirus (long COVID) [updated 03-31-2022]

Case Investigation & Contact Tracing
Canada
- Public health management of cases and contacts associated with COVID-19 [02-04-2022]

Ontario
- COVID-19 fully immunized and previously positive individuals: case, contact and outbreak management interim guidance v 3 [10-12-2021]
- Management of cases and contacts of COVID-19 in Ontario (version 13.0) [08-11-2021]
- Appendix 8: cases with positive COVID-19 serology results and management of cases with multisystem inflammatory syndrome in children (MIS-C) temporally associated with COVID-19. Version 2.0 [02-18-2021]
- Appendix 10: case & contact management COVID-19 surge support model (pilot) [01-21-2021]
Canadian provinces and territories (other than Ontario)

- BC Interim guidance: public health management of cases and contacts associated with novel coronavirus (COVID-19) in the community [03-16-2022]

WHO

- Contact tracing and quarantine in the context of the Omicron SARS-CoV-2 variant: interim guidance [02-17-2022]
- Considerations for quarantine of contacts of COVID-19 cases [06-25-2021]
- Operational guide for engaging communities in contact tracing [05-28-2021]
- Contact tracing in the context of COVID-19 [02-01-2021]

CDC

- Quarantine and isolation [updated 03-30-2022]
- Contact tracer’s interview tool: notifying people about an exposure to COVID-19 [02-28-2022]
- Interim guidance on developing a covid-19 case investigation & contact tracing plan: overview [02-28-2021]
- Prioritizing case investigations and contact tracing for covid-19 in high burden jurisdictions [02-28-2022]
- Schools, child care, and colleges [02-07-2022]
- Contact tracing for COVID-19 [02-10-2022]
- Investigating a COVID-19 case [01-21-2022]
- Ending home isolation for persons with COVID-19 not in healthcare settings [01-14-2022]
- COVID-19 contact tracing communications toolkit for health departments [11-05-2021]
- Contact tracing resources for health departments [09-23-2021]
- Global contact tracing [01-15-2021]

UK

- COVID-19: investigation and initial clinical management of possible cases [updated 03-25-2022]
- Guidance for contacts of people with confirmed coronavirus (COVID-19) infection who do not live with the person [02-15-2022]

ECDC

- Contact tracing in the European Union: public health management of persons, including healthcare workers, who have had contact with COVID-19 cases – 4th update [10-28-2021]
- Indicator framework to evaluate the public health effectiveness of digital proximity tracing solutions [06-28-2021]

Infection Prevention and Control

PHAC / Health Canada

- Federal/provincial/territorial public health response plan for ongoing management of COVID-19 [03-31-2022]
- Evaluating COVID-19 disease transmission and public health measures in schools: outbreak investigation guidance [01-07-2022]
- Update with consideration of Omicron – interim COVID-19 infection prevention and control in the health care setting when COVID-19 is suspected or confirmed—December 23, 2021 [12-24-2021]
- At home: using ventilation and filtration to reduce the risk of aerosol transmission of COVID-19 [12-15-2021]
- COVID-19 medical masks and N95 respirators: overview [11-29-2021]
- COVID-19: guidance on indoor ventilation during the pandemic [01-18-2021]

Ontario
- Infection prevention and control hubs [11-10-2020]

Canadian provinces and territories (other than Ontario)
- QC COVID-19: evaluation of disinfection options for N95 filtering facepiece respirators in the context of the pandemic [01-13-2022]
- QC COVID-19: disinfection of N95 single-use filtering facepiece respirators [01-13-2022]
- BC COVID-19: outbreak management protocol for acute care settings [02-02-2022]

WHO
- Annex to Infection prevention and control during health care when coronavirus disease (COVID-19) is suspected or confirmed [10-01-2021]
- Infection prevention and control during health care when coronavirus disease (COVID-19) is suspected or confirmed [07-12-2021]
- Roadmap to improve and ensure good indoor ventilation in the context of COVID-19 [03-01-2021]

CDC
- Interim infection prevention and control recommendations to prevent SARS-CoV-2 spread in nursing homes [02-02-2022]
- Considerations for inpatient obstetric healthcare settings [11-19-2021]
- Cleaning and disinfecting your facility: every day and when someone is sick [11-15-2021]

ECDC
- Risk of SARS-CoV-2 transmission from newly-infected individuals with documented previous infection or vaccination [03-29-2021]
• Infection prevention and control and preparedness for COVID-19 in healthcare settings - sixth update [02-09-2021]
• Coronavirus disease 2019 (COVID-19) and supply of substances of human origin in the EU/EEA - Second update [12-10-2020]
• Guidelines for the use of non-pharmaceutical measures to delay and mitigate the impact of 2019-nCoV [09-24-2020]

UK
• COVID-19: infection prevention and control (IPC) [03-15-2022]
• Coronavirus (COVID-19): safer public places - managing public outdoor settings [02-22-2022]
• Technical specifications for personal protective equipment (PPE) [02-14-2022]
• COVID-19: guidance for stepdown of infection control precautions and discharging COVID-19 patients from hospital to home settings [01-17-2022]
• Ventilation of indoor spaces to stop the spread of coronavirus (COVID-19) [09-15-2021]

Section II: Guidelines for Health Sectors

Healthcare Providers

Ontario Ministry of Health
• COVID-19 interim guidance: Omicron surge management of critical staffing shortages in highest risk settings, Version 3.0 [updated 03-31-2022]
• COVID-19 guidance: acute care v.7 [02-16-2022]
• COVID-19 guidance: primary care providers in a community setting: version 10.0 [02-14-2022]

Canada
• COVID-19 pandemic guidance for the health care sector: 4.3 human resources [04-22-2020]

WHO
• COVID-19 home care bundle for health care workers [02-09-2022]
• Global pulse survey on continuity of essential health services during the COVID-19 pandemic [02-07-2022]
• Third round of the global pulse survey on continuity of essential health services during the COVID-19 pandemic [02-07-2022]
• Diagnostics, therapeutics, vaccine readiness, and other health products for COVID-19: Interim guidance [07-07-2021]
• COVID-19: occupational health and safety for health workers: interim guidance [02-02-2021]
• Rapid hospital readiness checklist: interim guidance [11-26-2020]

CDC
• Interim guidance for managing healthcare personnel with SARS-CoV-2 infection or exposure to SARS-cov-2 [01-21-2022]
• Staff shortages [01-21-2022]
• Operational considerations for the identification of healthcare workers and inpatients with suspected COVID-19 in non-U.S. healthcare settings [01-14-2022]
**UK**
- COVID-19: management of staff and exposed patients and residents in health and social care settings [updated 04-01-2022]
- Contract tracing in the European Union: public health management of persons, including healthcare workers, who have had contact with COVID-19 cases – fourth update [10-28-2021]

**First Responders, Dentistry, Pharmacy, and Allied Health**

**Ontario Ministry of Health**
- Novel coronavirus (COVID-19) guidance for paramedic services; version 4 [10-01-2020]

**PHAC**
- Evidence to support safe return to clinical practice by oral health professionals in Canada during the COVID-19 pandemic: a report prepared for the Office of the Chief Dental Officer of Canada Ontario Ministry of Health [02-02-2022]

**WHO**
- Maintaining a safe and adequate blood supply during the pandemic outbreak of coronavirus disease (COVID-19): interim guidance [02-17-2021]

**CDC**
- Evaluation for SARS-CoV-2 testing in animals [updated 03-30-2022]

**UK**
- COVID-19: guidance for first responders [03-08-2022]

**Other**
- COVID-19: guidance for the use of teledentistry Royal College of Dental Surgeons of Ontario [no date]

**Death Services**

**Ontario**
- ON Bereavement Authority of Ontario COVID-19 [03-17-2022]

**WHO**
- Infection prevention and control for the safe management of a dead body in the context of COVID-19: interim guidance [09-04-2020]

**CDC**
- Recommendations for Tribal ceremonies & gatherings [09-30-2021]
- Collection and submission of postmortem specimens from deceased persons with known or suspected COVID-19: interim guidance [12-02-2020]
Handling the deceased with suspected or confirmed COVID-19 [04-01-2022]

COVID-19: guidance for arranging or attending a funeral or commemorative event [03-22-2022]

QC COVID-19: preventive and protective measures for funeral services businesses [07-30-2021]

Congregate Living (including Long-Term Care, Prisons, and Shelters)

Ontario Ministry of Health
- COVID-19 screening tool for long-term care homes and retirement homes: version 9 [03-18-2022]
- Retirement homes policy to implement directive #3 [12-27-2021]
- COVID-19 guidance: home and community care providers: version 6 [05-21-2021]

PHAC
- COVID-19: guidance on pets and long-term care homes [07-20-2021]
- Using ventilation and filtration to reduce aerosol transmission of COVID-19 in long-term care homes [04-12-2021]
- COVID-19 guidance for long-term care facilities and nursing homes in Indigenous communities [04-14-2020]

WHO
- Infection prevention and control guidance for long-term care facilities in the context of COVID-19 update: interim guidance [01-08-2021]

CDC
- How to protect yourself and others [02-25-2022]
- Recommendations for quarantine duration in correctional and detention facilities [02-15-2022]
- Investigating cases in homeless shelters [02-10-2022]
- Interim guidance on people experiencing unsheltered homelessness [02-10-2022]
- Interim guidance for SARS-CoV-2 testing in homeless shelters and encampments [02-10-2022]
- Correctional and detention facilities [02-10-2022]
- Interim guidance for homeless service providers to plan and respond to Coronavirus Disease 2019 (COVID-19) [02-10-2022]
- Infection control for nursing homes [02-02-2022]
- Interim guidance for general population disaster shelters during the COVID-19 pandemic [08-30-2021]
• Interim guidance for health departments: COVID-19 vaccination implementation for people experiencing homelessness [04-30-2021]
• Performing broad-based testing for SARS-CoV-2 in congregate correctional, detention, and homeless service settings [03-29-2021]

UK
• Visiting someone in prison [updated 04-01-2022]
• COVID-19: admission and care of people in care homes [03-22-2022]
• Preventing and controlling outbreaks of COVID-19 in prisons and places of detention [03-21-2022]
• COVID-19: provision of night shelters [03-10-2022]
• COVID-19: guidance for hostel services for people experiencing homelessness and rough sleeping [03-07-2022]
• Data collection on COVID-19 outbreaks in closed settings with a completed vaccination programme: long-term care facilities, v. 2.1 [02-18-2022]
• COVID-19: how to work safely in domiciliary care in England [01-24-2022]
• Management of acute respiratory illness in prisons and places of detention [12-10-2021]
• Surveillance of COVID-19 in long-term care facilities in the EU/EEA [11-29-2021]
• COVID-19: national framework for prison regimes and services [08-18-2021]
• COVID-19: how to work safely in care homes [08-16-2021]
• COVID-19 guidance for prison settings v 1.0 [07-16-2021]
• Infection control in prisons and places of detention [07-01-2011]

Canadian provinces and territories (other than Ontario)
• BC Visitor guidance for long-term care and seniors' assisted living [updated 03-18-2022]
• BC COVID-19 outbreak management protocol for long-term care and seniors’ assisted living settings [02-02-2022]

Other
• CSC Testing of inmates in federal correctional institutions for COVID-19 [updated 03-31-2022]

Section III: Guidelines for the Community

Travel, Transport & Borders

Ontario Ministry of Health
• Travelling during COVID-19 [updated 03-21-2022]
• Guidance for public transit agencies and passengers in response to COVID-19 [updated 03-21-2022]

Canada
• Official global travel advisories [updated often]
• Provincial and territorial restrictions [03-17-2022]
• COVID-19: exposure notices from select cruise ships [03-11-2022]
• COVID-19: travel, testing, quarantine and borders [03-08-2022]
- Guidance material for air operators managing travellers during the check-in procedure for flights departing from an aerodrome in Canada [11-16-2021]
- Federal safety guidance to protect drivers and limit the spread of COVID-19 in commercial vehicle operations [06-24-2021]

**CDC**
- COVID-19 travel recommendations by destination [updated 03-28-2022]
- Stay up to date with your COVID-19 vaccines [updated 03-30-2022]
- Requirement for proof of COVID-19 vaccination for air passengers [03-03-2022]
- Requirement for proof of negative COVID-19 test or recovery from COVID-19 for all air passengers arriving in the United States [01-27-2022]
- Required testing before air travel to the US [01-27-2022]

**WHO**
- An implementation guide for the management of COVID-19 on board cargo ships and fishing vessels [12-23-2021]
- WHO public health checklist for controlling the spread of COVID-19 in ships, sea ports and inland ports [10-00-2021]

**UK**
- People with symptoms of a respiratory infection including COVID-19 [04-01-2022]
- Carry out international road haulage [03-18-2022]
- Travel abroad from England during coronavirus (COVID-19) [03-18-2022]
- Coronavirus (COVID-19): cruise ship travel [03-17-2022]
- Working safely during coronavirus (COVID-19) [02-24-2022]
- Travel to England from another country during coronavirus (COVID-19) [03-18-2022]
- COVID-19: safer transport guidance for operators and people who work in or from vehicles [02-25-2022]
- Coronavirus (COVID-19): taxis and PHVs [02-25-2022]

**Other**
- Emergency response plan and action checklist for use by air carriers in the event of a public health emergency [no date]

**Schools / Childcare**

**Ontario Ministry of Health**
- COVID-19: health and safety measures at schools [updated 03-31-2022]
- COVID-19: health and safety measures for child care [updated 03-31-2022]
- COVID-19 integrated testing & case, contact and outbreak management interim guidance: Omicron surge [updated 03-28-2022]
- COVID-19 safety guidelines for: camps [03-01-2022]

**PHAC**
- Planning for the 2021-2022 school year in the context of COVID-19 vaccination [02-02-2022]
• **Evaluating COVID-19 disease transmission and public health measures in schools: outbreak investigation guidance** [01-07-2022]
• **COVID-19: organized summer activities for children and youth** [12-16-2021]

**CDC**
• **Considerations for institutions of higher education** [02-07-2022]
• **Schools, child care, and colleges** [updated 02-07-2022]
• **COVID-19 guidance for operating early care and education/child care programs** [01-28-2022]
• **Guidance for COVID-19 prevention in K-12 schools** [01-13-2022]

**UK**
• **Emergency planning and response for education, childcare, and children's social care settings** [04-01-2022]
• **Managing coronavirus (COVID-19) in education and childcare settings** [02-24-2022]

**Mental Health /Addiction /Inequity**

**Ontario Ministry of Health**
• **COVID-19: mental health resources for camp operators version 1.0** [07-13-2021]
• **Guidance for consumption and treatment services sites: version 2** [04-16-2020]
• **COVID-19 guidance: mental health and addictions service providers in community settings: version 2** [09-24-2020]

**PHAC**
• **Helping people who use substances during the COVID-19 pandemic** [07-06-2021]

**Provinces & Territories (excluding Ontario)**
• **BC COVID-19: harm reduction and overdose response** [01-07-2022]
• **AB Harm reduction and COVID-19: guidance document for community service providers** [12-08-2020]
• **QC COVID-19: tackling social isolation and loneliness among seniors in a pandemic context** [10-28-2020]
• **BC COVID-19: provincial episodic overdose prevention service (e-OPS) protocol** [06-26-2020]

**WHO**
• **Mental health and COVID-19: Early evidence of the pandemic's impact: Scientific brief, 2 March 2022** [03-02-2022]
• **Rise, respond, recover: renewing progress on women's, children's and adolescent's health in the era of COVID-19** [12-00-2021]
• **Social isolation and loneliness among older people: advocacy brief** [07-29-2021]
• **Smoking and COVID-19** [06-30-2020]
• **Addressing violence against children, women and older people during the COVID-19 pandemic: key actions** [06-18-2020]
• **COVID-19 and violence against women: what the health sector / system can do** [04-07-2020]
Coronavirus Disease 2019 (COVID-19): 04/01/2022

CDC / SAMHSA
- Substance abuse and mental health training and technical assistance related to COVID-19 [08-16-2021]
- Virtual recovery resources [07-00-21]
- Disaster planning handbook for behavioural health service programs [03-00-2021]
- Interim guidance for syringe services programs [05-15-2020]
- Considerations for the care and treatment of mental and substance use disorders in the COVID-19 epidemic: March 20, 2020 [05-07-2020]
- Considerations for crisis centers and clinicians in managing the treatment of alcohol or benzodiazepine withdrawal during the COVID-19 epidemic: March 19, 2020 [03-19-2020]
- Intimate partner violence and child abuse considerations during COVID-19 [no date]

UK
- Alcohol and drug misuse prevention and treatment guidance [updated 03-07-2022]
- Every Mind Matters: looking after your mental health [no date]
- Domestic abuse: how to get help [11-11-2021]

Other
- Public health ethics and COVID-19: selected resources [11-00-2021]
- Risk mitigation in the context of dual public health emergencies. Version 1.5 [03-00-20]

Community Ministry of Health
- COVID-19 public health measures and advice [03-21-2022]
- Guidance on community emergency evacuations: version 2 [07-06-2021]

PHAC
- Individual and community-based measures to mitigate the spread of coronavirus disease (COVID-19) in Canada [02-02-2022]
- COVID-19: organized summer activities for children and youth [12-16-2021]
- At home: using ventilation and filtration to reduce the risk of aerosol transmission of COVID-19 [12-15-2021]

WHO
- Key planning recommendations for mass gatherings in the context of COVID-19 [11-04-2021]

CDC
- Information about COVID-19, pets, and other animals [updated 03-31-2022]
- Operational considerations for community isolation centers [updated 03-30-2022]
- Breastfeeding & caring for newborns [01-20-2022]
- Interim guidance for general population disaster shelters during the COVID-19 pandemic [08-04-2021]
- COVID-19 response health equity strategy: accelerating progress towards reducing COVID-19 disparities and achieving health equity [08-21-2020]
• Considerations for owners and operators of multifamily housing including populations at increased risk for complications from COVID-19 [05-05-2021]

UK
• Living safely with respiratory infections, including COVID-19 [updated 04-01-2022]
• COVID-19: guidance for providers of accommodation for asylum seekers [03-21-2022]
• Guidance on coronavirus (COVID-19) measures for grassroots sport participants, providers and facility operators [03-04-2022]
• Supported living services during coronavirus (COVID-19) [03-04-2022]
• COVID-19: guidance for the safe use of places of worship [02-25-2022]
• Carrying out COVID-19 status checks at your venue or event [02-24-2022]

Australia
• Early aero-medical evacuation of COVID-19 cases and contacts from remote communities [08-20-2020]

Businesses/Workplaces
Ontario Ministry of Health
• COVID-19 and workplace health and safety [updated 03-28-2022]
• COVID-19 customer screening [03-21-2022]
• COVID-19 worker and employee screening [03-21-2022]
• Restaurant and food services health and safety during COVID-19 [01-31-2022]
• COVID-19 guidance: workplace outbreaks v2.0 [10-05-2021]
• Guidance for employers managing workers with symptoms within 48 hours of COVID-19 immunization [11-30-2021]

WHO
• Preventing and mitigating COVID-19 at work [05-19-2021]

CDC
• Workplaces & businesses: plan, prepare and respond [10-18-2021]
• Protecting workers: guidance on mitigating and preventing the spread of COVID-19 in the workplace [08-13-2021]

ECDC
• Considerations for the use of face masks in the community in the context of the SARS-CoV-2 Omicron variant of concern [02-07-2022]

UK
• Enabling safe and effective volunteering during coronavirus (COVID-19) [03-07-2022]
• Working safely during coronavirus (COVID-19) [02-24-2022]
• COVID-19: providing unpaid care [02-15-2022]

Other
• BC Guidance on return to work for health care workers with confirmed or suspected COVID-19 [09-22-2021]
• BC Guidance for outside dining spaces based on the Provincial Health Officer’s order to food and liquor serving premises [04-23-2021]
Masks (Non-Medical)

Ontario Ministry of Health
- Face coverings and face masks [updated 03-21-2021]

PHAC
- COVID-19 mask use: advice for community settings [02-01-2022]

WHO
- What are relevant, feasible and effective approaches to promote acceptance, uptake and adherence to physical distancing measures for COVID-19 prevention and control? [00-00-2021]
- Advice on the use of masks in the context of COVID-19 [12-01-2020]

CDC
- Your guide to masks [updated 02-25-2022]
- Use of masks to help slow the spread of COVID-19 [08-12-2021]

ECDC
- Use of gloves in healthcare and non-healthcare settings in the context of the COVID-19 pandemic [07-02-2020]

UK
- Face coverings: when to wear one, exemptions, and how to make one [01-27-2022]
- The Disabled Persons Transport Advisory Committee (DPTAC) position on face coverings [03-22-2021]

Other
- BC Face coverings (COVID-19) [12-03-2021]